Hypopharynx squamous cell carcinoma
diseaseOn this page
Also known as epidermoid carcinoma of hypopharynxepidermoid carcinoma of the hypopharynxhypopharyngeal epidermoid carcinomahypopharyngeal squamous cell carcinomahypopharyngeal throat squamous cell cancersquamous cell carcinoma of hypopharynx
Summary
Hypopharynx squamous cell carcinoma (MONDO:0044638) is a cancer and 61 clinical trials. Top therapeutic interventions include cisplatin, cetuximab, and atezolizumab. A subtype of pharyngeal squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 61
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1.27 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hypopharynx squamous cell carcinoma |
| Mondo ID | MONDO:0044638 |
| EFO | EFO:1001960 |
| Orphanet | 494547 |
| ICD-11 | 680629191 |
| NCIT | C4043 |
| UMLS | C0280321 |
| MedGen | 79102 |
| GARD | 0017907 |
| Anatomy (UBERON) | UBERON:0001051 |
| Is cancer (heuristic) | yes |
Also known as: epidermoid carcinoma of hypopharynx · epidermoid carcinoma of the hypopharynx · hypopharyngeal epidermoid carcinoma · hypopharyngeal squamous cell carcinoma · hypopharyngeal throat squamous cell cancer · squamous cell carcinoma of hypopharynx
Data availability: 39 cell lines.
Disease family
This is a subtype of pharyngeal squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › pharynx cancer › pharyngeal squamous cell carcinoma › hypopharynx squamous cell carcinoma
Related subtypes (1): oropharynx squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Cisplatin | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 61.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 27 |
| PHASE1 | 16 |
| Not specified | 6 |
| PHASE3 | 5 |
| PHASE2/PHASE3 | 4 |
| EARLY_PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT01810913 | PHASE2/PHASE3 | RECRUITING | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer |
| NCT05063552 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers |
| NCT05333523 | PHASE3 | RECRUITING | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. |
| NCT05721755 | PHASE3 | ACTIVE_NOT_RECRUITING | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT06589804 | PHASE3 | RECRUITING | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment |
| NCT01439724 | PHASE3 | COMPLETED | Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients |
| NCT03258554 | PHASE2/PHASE3 | COMPLETED | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
| NCT05050162 | PHASE2/PHASE3 | SUSPENDED | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer |
| NCT00494182 | PHASE2 | ACTIVE_NOT_RECRUITING | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| NCT02734537 | PHASE2 | RECRUITING | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery |
| NCT03468218 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer |
| NCT04671667 | PHASE2 | RECRUITING | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma |
| NCT04858269 | PHASE2 | ACTIVE_NOT_RECRUITING | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients |
| NCT04862650 | PHASE2 | ACTIVE_NOT_RECRUITING | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT05136196 | PHASE2 | RECRUITING | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study |
| NCT05172258 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck |
| NCT06137378 | PHASE2 | RECRUITING | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] |
| NCT06532279 | PHASE2 | RECRUITING | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer |
| NCT06636734 | PHASE2 | RECRUITING | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial |
| NCT06980038 | PHASE2 | RECRUITING | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer |
| NCT07058805 | PHASE2 | RECRUITING | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer |
| NCT07063212 | PHASE2 | RECRUITING | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) |
| NCT07423078 | PHASE2 | RECRUITING | Window of Opportunity in Preserving Laryngeal Function Trial |
| NCT00458978 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer |
| NCT01064479 | PHASE2 | COMPLETED | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| NCT01256385 | PHASE2 | COMPLETED | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
| NCT01267240 | PHASE2 | TERMINATED | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
| NCT02007200 | PHASE2 | COMPLETED | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery |
| NCT02196168 | PHASE2 | TERMINATED | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT03342911 | PHASE2 | COMPLETED | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
| NCT04296747 | PHASE2 | UNKNOWN | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer |
| NCT04445064 | PHASE2 | TERMINATED | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. |
| NCT04541355 | PHASE2 | COMPLETED | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin |
| NCT04831450 | PHASE2 | WITHDRAWN | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) |
| NCT06084845 | PHASE2 | WITHDRAWN | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer |
| NCT02567422 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer |
| NCT04533750 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
| NCT04576091 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer |
| NCT05172245 | PHASE1 | RECRUITING | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 19 |
| CETUXIMAB | 4 | 4 |
| ATEZOLIZUMAB | 4 | 2 |
| CABOZANTINIB | 4 | 2 |
| CEMIPLIMAB | 4 | 2 |
| DURVALUMAB | 4 | 1 |
| LOVASTATIN | 4 | 1 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| IPATASERTIB | 3 | 2 |
| CEDIRANIB MALEATE | 3 | 1 |
| GANETESPIB | 3 | 1 |
| XEVINAPANT | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| BERZOSERTIB | 2 | 1 |
| ETIMUPEPIMUT | 2 | 1 |
| IMSAPEPIMUT | 2 | 1 |
| IRX-2 | 2 | 1 |
| ONALESPIB | 2 | 1 |
| SOY ISOFLAVONES | 2 | 1 |
| CHEMBL5412235 | 0 | 2 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| CHEMBL3753202 | 0 | 1 |
| EXELIXIS | 0 | 1 |